Infection in critically ill patients: Clinical impact and management

Current Opinion in Infectious Diseases

Volumn 16, Issue 4, 2003, Pages 309-313

  Vincent, Jean Louis ^a   Jacobs, Frédérique ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Antimicrobial resistance; Septic shock; Severe sepsis

Indexed keywords

ANTIBIOTIC AGENT; DROTRECOGIN; FLUDROCORTISONE; HYDROCORTISONE; IMMUNOMODULATING AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; ERADICATION THERAPY; HEMODYNAMICS; HUMAN; IMMUNOMODULATION; INFECTION; INFECTION CONTROL; MORTALITY; REVIEW; SEPSIS; STEROID THERAPY; SURGICAL TECHNIQUE;

EID: 0041700066     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200308000-00002     Document Type: Review

References (22)

1. Bone RC, Balk RA, Cerra FB, et al. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
2. Vincent JL. Sepsis definitions. Lancet Infect Dis 2002; 2:135. This provides the first description of the PIRO concept to characterize patients with sepsis.
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceInternational Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256. This paper is the final report of the Sepsis Definitions Conference covering current approaches to the diagnosis and definition of sepsis and introducing the PIRO concept.
4. Appoloni O, Dupont E, Andrien M, et al. Association of TNF2, a TNFα promoter polymorphism, with plasma TNFα levels and mortality in septic shock. Am J Med 2001; 110:486-488.
5. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-336.
6. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191.
7. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentric, prospective study. Crit Care Med 1998; 26:1793-1800.
8. Vincent JL, Bihari D, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: The results of the EPIC study. JAMA 1995; 274:639-644.
9. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-121. This provides important epidemiological data on sepsis in Europe.
10. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
11. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701.
12. Hanon FX, Monnet DL, Sorensen TL, et al. Survival of patients with bacteraemia in relation to initial empirical antimicrobial treatment. Scand J Infect Dis 2002; 34:520-528.
13. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-66.
14. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001; 27 (Suppl 1):S33-S48.
15. Task Force of the American College of Critical Care Medicine. SoCCM: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27:639-660.
16. Vincent JL. Hemodynamic support in septic shock: Guidelines for the management of severe sepsis and septic shock. International Sepsis Forum. Intensive Care Med 2001; 27 (Suppl 1):S80-S92.
17. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
18. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
19. Angus DC, Laterre PF, Helterbrand J, et al. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 2002; 122 (suppl):51S (abstract)
20. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834-840. This paper shows the beneficial effects of this drug on organ function, in addition to its known effects on mortality.
21. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871. This study helps clarify the place of steroids in the treatment of patients with septic shock, after many years of debate.
22. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med 2003; 138:502-505.